Form 4 for VNDA Vanda Pharmaceuticals Inc.
Accepted 2021-09-17 00:00:00 ET · period of report 2021-09-15 · accession 0001209191-21-056530 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2021-09-17 | 2021-09-15 | VNDA | Jones Aranthan II | Chief Corp. Affairs Off | M - OptEx | $11.66 | +12.1K | 91.0K | +15% | +$141.3K |
| D | 2021-09-17 | 2021-09-15 | VNDA | Jones Aranthan II | Chief Corp. Affairs Off | S - Sale+OE | $16.49 | -16.8K | 82.0K | -17% | -$277.4K |
| DM | 2021-09-17 | 2021-09-15 | VNDA | Jones Aranthan II | Chief Corp. Affairs Off | M - OptEx | $0.00 | -12.1K | 33.2K | -27% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2021-09-15 | M | A | 7,842 | $11.32 | 98,804 | D | — | — | |
| 2 | Common | Common Stock | 2021-09-15 | M | A | 4,277 | $12.27 | 90,962 | D | — | — | |
| 3 | Common | Common Stock | 2021-09-15 | S | D | 16,824 | $16.49 | 81,980 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.40 to $16.605, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. |
| 4 | Derivative | Employee Stock Option (Right to Buy) | 2021-09-15 | M | D | 7,842 | $0.00 | 47,158 | D | $11.32 · — to 2030-02-25 | 7,842 Common Stock | (F4) The option vested with respect to 25% of the underlying shares on February 26, 2021, with the balance vesting in equal monthly installments over the next 36 months of continuous service thereafter, provided the Reporting Person remains continuously employed by the Issuer through the applicable vesting date. |
| 5 | Derivative | Employee Stock Option (Right to Buy) | 2021-09-15 | M | D | 4,277 | $0.00 | 33,224 | D | $12.27 · — to 2029-07-24 | 4,277 Common Stock | (F3) The option vested with respect to 25% of the underlying shares on July 25, 2020, with the remaining 75% of the shares vesting in 36 equal monthly installments beginning August 25, 2020, provided the Reporting Person remains continuously employed by the Issuer through each monthly vesting date. |